February 13, 2024
SaNOtize to Evaluate Nitric Oxide Nasal Spray for the Treatment of SinusitisSeptember 27, 2023
SaNOtize’s Board Appoints Steven Basta as New Chief Executive OfficerMay 16, 2023
ECRAID‑Prime and SaNOtize to Begin Trial on Antiviral Nasal SprayJanuary 24, 2023
SaNOtize Announces Inaugural Scientific Advisory BoardJanuary 17, 2023
SaNOtize Names John Sharp Chief Financial OfficerAugust 24, 2022
SaNOtize Announces $24 Million in Series B Funding to Advance Its Nitric Oxide-Based TherapeuticsJuly 13, 2022
Phase 3 Study Shows SaNOtize Nasal Spray Reduced Viral Load by 99% in Two Days Glenmark & SaNOtize Peer-Reviewed Publication in The LancetMay 11, 2022
Clinical Study Suggests SaNOtize Spray Effective at Preventing COVID-19 After High-Risk ExposureFebruary 9, 2022
Phase 3 Clinical Trial Confirms 99% Efficacy; Approved in India Glenmark Launches FabiSpray® in India Positive Phase 3 Trial Results for NONS (FabiSpray®)August 2, 2021
SaNOtize & Glenmark Sign Commercialization Agreement Commercialization of Nasal Spray for COVID-19 TreatmentJuly 8, 2021
Anti-Viral Treatment Made Available in Israeli PharmaciesJune 23, 2021
Health Canada Approves Phase III COVID-19 TrialsMarch 15, 2021
UK Clinical Trial Confirms Breakthrough TreatmentJanuary 10, 2021
Covid-Busting Nasal Spray Begins UK TrialsJune 3, 2020
Life Sciences See Silver Lining in Dark COVID CloudsJune 2, 2020
Potential COVID-19 Treatment Tested in MontrealFour sites open in Quebec for new patients.
May 31, 2020
Could a Simple Gas Produced by Our Bodies Treat COVID-19? Canadian Trials UnderwayMay 25, 2020
SaNOtize Phase II COVID Prevention & Treatment Trial UnderwayApril 22, 2020
SaNOtize Obtains Health Canada Approval for Phase II TrialSaNOtize received a CAD 400,000 NRC-IRAP grant.
March 12, 2020
SaNOtize closes a $1 million investment from OurCrowd.
February 25, 2020
SaNOtize welcomes Nobel laureate Ferid Murad, M.D., Ph.D. to its Board of Directors.
December 30, 2019
SaNOtize awarded $1.2 million from U.S. Dept. of Defence for phase I diabetic foot ulcer trial.
November 28, 2019
First patient enrolled in chronic sinusitis Phase II clinical trial.
July 2019
Health Canada issues No Objection Letter for chronic sinusitis Phase II trial.
June 2019
Health Canada issues No Objection Letter for diabetic foot ulcer Phase I trial.
March 2019
SaNOtize named to 2019 “Ready to Rocket” list.
February 2019
SaNOtize secures $450,000 USD seed investment and commences chronic sinusitis dose escalation trial.
November 2018
Partnership with SPIRE Bioventures to expand Bay Area presence and accelerate growth.
October 2018
Health Canada issues No Objection Letter for chronic sinusitis trial; IRAP grant awarded for Onychomycosis device.
August 2018
Finalist for Innovation Challenge at RESI Boston, September 6, 2018.
May 2018
Angel investment of $200K USD received.
January 2018
Presentation at Biotech Showcase™ Annual Conference, January 10, 2018, Hilton San Francisco Union Square:
- Date: January 10, 2018
- Time: 9:15 AM (PST)
- Room: Franciscan B
- Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
Overview of NORS™ platform, patent portfolio, and clinical stage development strategy.